Francesco Impagnatiello
Overview
Explore the profile of Francesco Impagnatiello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galli C, Bastia E, Hubatsch D, Toris C, Fan S, Unser A, et al.
J Ocul Pharmacol Ther
. 2023 Dec;
40(6):389-396.
PMID: 38088745
To determine NCX 470 (0.1%) and Lumigan (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics....
2.
Sgambellone S, Marri S, Villano S, Masini E, Provensi G, Bastia E, et al.
Transl Vis Sci Technol
. 2023 Sep;
12(9):22.
PMID: 37750744
Purpose: The purpose of this study was to assess the retinal protective activity and ocular hemodynamics after NCX 470 (0.1%) compared to bimatoprost administered as the US Food and Drug...
3.
Bastia E, Sgambellone S, Lucarini L, Provensi G, Brambilla S, Galli C, et al.
J Ocul Pharmacol Ther
. 2022 Jul;
38(7):496-504.
PMID: 35787180
Determine whether NCX 470, a nitric oxide (NO)-donating bimatoprost with clinically demonstrated intraocular pressure (IOP)-lowering effects, improves ocular hemodynamics and retinal physiology. Endothelin-1 (ET-1)-induced ischemia/reperfusion model in New Zealand white...
4.
Bastia E, Toris C, Brambilla S, Galli C, Almirante N, Bergamini M, et al.
Invest Ophthalmol Vis Sci
. 2021 Mar;
62(3):17.
PMID: 33704360
Purpose: NCX 667, a novel nitric oxide (NO) donor with an isomannide core, was characterized for its IOP-lowering ability in animal models of ocular hypertension and glaucoma. Bioengineered human trabecular...
5.
Bastia E, Toris C, Bukowski J, Brambilla S, Galli C, Almirante N, et al.
J Ocul Pharmacol Ther
. 2021 Feb;
37(4):215-222.
PMID: 33595367
We studied the IOP-lowering effects of NCX 1741, a novel nitric oxide (NO)-donating derivative of the phosphodiesterase type-5 inhibitor, avanafil, in Cynomolgus monkey with laser-induced ocular hypertension (OHT-monkeys). NCX 1193...
6.
Impagnatiello F, Bastia E, Almirante N, Brambilla S, Duquesroix B, Kothe A, et al.
Br J Pharmacol
. 2018 Apr;
176(8):1079-1089.
PMID: 29669171
In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage. PG...
7.
Blangetti M, Rolando B, Chegaev K, Guglielmo S, Lazzarato L, Durante M, et al.
Bioorg Med Chem Lett
. 2016 Dec;
27(3):479-483.
PMID: 28027869
A small series of water-soluble NO-donor furoxans bearing a basic center at the 4-position, having a wide lipophilic-hydrophilic balance range, and endowed with different NO-release capacities, were synthesized and characterized....
8.
Varani K, Vincenzi F, Targa M, Ravani A, Bastia E, Storoni L, et al.
J Pharmacol Exp Ther
. 2016 Feb;
357(2):240-7.
PMID: 26907623
NCX1404 [(3S)-5-methyl-3-(((1-(4-(nitrooxy)butanoyloxy)ethoxy)carbonylamino) methyl)hexanoic acid] is a novel nitric oxide (NO)-donating pregabalin that is readily absorbed and processed in vivo to pregabalin and NO. We determined the antiallodynic response of NCX1404...
9.
Impagnatiello F, Toris C, Batugo M, Prasanna G, Borghi V, Bastia E, et al.
Invest Ophthalmol Vis Sci
. 2015 Oct;
56(11):6558-64.
PMID: 26457541
Purpose: The prostaglandin F2alpha (PGF2α) analogue bimatoprost lowers intraocular pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. With the aim to enhance the...
10.
Cavet M, Vittitow J, Impagnatiello F, Ongini E, Bastia E
Invest Ophthalmol Vis Sci
. 2014 Aug;
55(8):5005-15.
PMID: 25125670
The predominant risk factor for the progression of glaucoma is an increase in IOP, mediated via a reduction in aqueous outflow through the conventional (trabecular meshwork and Schlemm's canal) outflow...